Halozyme presents new data from Ultrafast Insulin development program at 70th ADA

Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced Phase 2 results demonstrating that the subcutaneous coinjection of rHuPH20 (recombinant human hyaluronidase, PH20) with lispro significantly improves postprandial hyperglycemia, reduces hypoglycemia, and accelerates the absorption of mealtime insulin in patients with type 2 diabetes. Significantly more patients receiving lispro+PH20, 71% versus 48%, achieved the American Diabetes Association (ADA) goal of maintaining glucose below 180 mg/dL compared to lispro treatment alone, an indication of reduced hyperglycemia. Fewer patients required treatment for hypoglycemia and the mean minimum concentration for postprandial glucose was significantly higher for the lispro+PH20 combination compared to lispro alone.

Halozyme presented these results at the American Diabetes Association 70th Scientific Sessions today in Orlando, Fla. The results of this study confirm previously reported pharmacokinetic and glucodynamic findings in healthy volunteers and type 1 diabetes patients.

"The new data from our Ultrafast Insulin development program provide further evidence that the combination of our rHuPH20 enzyme with insulin reduces glucose excursions through enhanced insulin absorption," stated Jonathan Lim, M.D., Halozyme's president and CEO. "Less hyperglycemia and hypoglycemia with a faster acting, best-in-class insulin product could lead to a much better treatment for diabetes." The goal of Halozyme's Ultrafast Insulin program is to develop a mealtime insulin for patients with type 1 or type 2 diabetes that allows patients to better manage their blood glucose levels and safely reach treatment goals without excessive hypoglycemia.